Currently, the sequelae and short-term medical and psychological impact of the sars-cov-2 infection ("CoVID-19") remain poorly described. The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital.
Since sars-cov-2 ("CoVID-19") is a newly defined infection, its sequelae and short-term medical and psychological impact remain poorly described.The clinical and functional sequelae that may persist after acute sars-cov-2 ("CoVID-19") infection are essential to explore, in order to ensure the best possible follow-up of patients after discharge from hospital. Indeed, some patients may develop chronic respiratory failure, pulmonary fibrosis, or other comorbidities including cardiovascular or metabolic diseases. The psychological impact is also essential to assess. The sequelae and comorbidities of patients could also vary depending on the severity of the initial acute involvement. Investigators propose to explore the sequelae of patients who have been hospitalized for acute sars-cov-2 infection, between 3 to 6 months after discharge from hospital, by characterizing the incidence of chronic respiratory failure and fibrosis, as well as of various comorbidities such as cardiovascular, metabolic, and psychological diseases.
Study Type
OBSERVATIONAL
Enrollment
119
the incidence of chronic respiratory failure and fibrosis, as well as of comorbidities including cardiovascular, metabolic, renal, hepatic, neurological, and psychological diseases
University hospital of Montpellier
Montpellier, France
Development or worsening of a ventilatory disorder and/or chronic respiratory failure assessed by spirometry
Time frame: 3 to 6 months after Sars coV 2 infection
Assessment of dyspnea
assessed by 0-10 Borg scale
Time frame: 3 to 6 months after Sars coV 2 infection
Description of pulmonary lesions as assessed by lung CT scan
assessed by lung CT scan
Time frame: 3 to 6 months after Sars coV 2 infection
Development of pulmonary fibrosis as assessed by lung CT scan
assessed by lung CT scan
Time frame: 3 to 6 months after Sars coV 2 infection
Incidence or worsening of cardiovascular diseases
assessed by incidence of cardiovascular events, venous thromboembolism, and transthoracic echocardiogram
Time frame: 3 to 6 months after Sars coV 2 infection
Incidence or worsening of renal disease
renal function and urinary parameters
Time frame: 3 to 6 months after Sars coV 2 infection
Incidence or worsening of liver disease
hepatic blood parameters
Time frame: 3 to 6 months after Sars coV 2 infection
Incidence or worsening of psychological pathology : anxiety
assessed by validated scale: Generalized Anxiety Disorder-7 (GAD7)
Time frame: 3 to 6 months after Sars coV 2 infection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence or worsening of psychological pathology: depression
assessed by validated scales: Patient Health Questionnaire-9 (PHQ9)
Time frame: 3 to 6 months after Sars coV 2 infection
Incidence or worsening of psychological pathology: post-traumatic stress
assessed by validated scale : Post-traumatic Checklist for DSM-5 (PCL-5)
Time frame: 3 to 6 months after Sars coV 2 infection
Incidence or worsening of psychological pathology: insomnia
assessed by validated scale : insomnia severity index (ISI)
Time frame: 3 to 6 months after Sars coV 2 infection
Assessment of the health-related quality of life
assessed by validated scale (EQ-5D-L questionnaire)
Time frame: 3 to 6 months after Sars coV 2 infection
Assessment of the fatigue
assessed by the fatigue severity sale
Time frame: 3 to 6 months after Sars coV 2 infection
Assessment of the socioeconomic deprivation
assessed by the Evaluation of Deprivation and Inequalities in Health Examination (EPICES) scale
Time frame: 3 to 6 months after Sars coV 2 infection
development or worsening of metabolic disorders: diabetes, thyroid diseases, dyslipidemia, adrenal disorders, malnutrition
assessed by blood glucose level, HbA1C, lipid blood tests, TSH, T3, T4, antithyroperoxydase antibodies, cortisol, ACTH, renin, aldosteron, albumin level, vitamin D level, iron status, weight changes
Time frame: 3 to 6 months after Sars coV 2 infection
Development of auto-immune disorders
assessed by lupus anticoagulant, anti-cardiolipin, anti-β2-glycoprotein
Time frame: 3 to 6 months after Sars coV 2 infection
Assessment of the evolution of the humoral anti-SARS-CoV-2 immunization profile
Presence and levels of anti-SARS-CoV-2 antibodies of IgG, IgA and IgM isotypes
Time frame: 3 to 6 months after Sars coV 2 infection
Patients' self-reported level of physical activity
assessed by the International Physical Activity Questionnaire (IPAQ)
Time frame: 3 to 6 months after Sars coV 2 infection
Determination of risk factors associated with sequelae or comorbidities
Time frame: 3 to 6 months after Sars coV 2 infection